Influenza & Respiratory

 

 

This event will tackle the latest issues affecting vaccines for respiratory diseases including influenza, TB, RSV and MERS to stimulate the industry to develop more effective vaccines. Ensure you use this event to make people aware of your expertise around key topics such as universal and seasonal flu, maternal immunization and pandemic preparedness.

 

DOWNLOAD DRAFT AGENDA

 

2018 AGENDA

 

Influenza & Respiratory, Wednesday 4 April 2018

RSV Vaccines & Maternal Immunization

Dr Martin Moore
Influenza & Respiratory
09:40

Achieving an effective balance of attenuation and immunogenicity for RSV live attenuated vaccines (LAV)

·         Engineering RSV LAV strains with enhanced immunogenicity using a multi-faceted, rational mutagenesis approach

·         Enhancing expression of the pre-fusion conformation of the RSV fusion (F) protein

·         Using genetic mapping to identify residues that correlate with pre-fusion antigen maintenance and thermal stability of infectivity into LAV candidates

·         Candidates exhibiting elevated pre-fusion antigen levels, thermal stability, immunogenicity, and efficacy

10:40

Networking coffee break

Dr Gregory Glenn
Influenza & Respiratory
11:40

The RSV F Nanoparticle Vaccine for Infants via Maternal Immunization in Phase 3: Rationale and Update

Dr Koert Stittelaar
Influenza & Respiratory
12:10

Building further on Viroclinics Ferret model with novel insights: Transmission of HRSV in Immunocompromised ferrets

·         Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) from immunocompromised ferrets to both immunocompromised and immunocompetent ferrets

·         Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry

·         A high transmission rate of HRSV was found and more …

Dr Natalie Mazur
Influenza & Respiratory
12:40

Landscape analysis of RSV vaccine development and future implications

Universal and Pandemic Influenza Vaccines

Dr Sean Tucker
Influenza & Respiratory
12:55

Comparisons between QIV and Vaxart’s oral vaccine for protection against influenza challenge in humans

1:10

Networking Lunch & Poster Session

Dr Brian Ward
Influenza & Respiratory
2:40

Characterization of the immune response induced by plant-made influenza vaccines

Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly

·         Phase 2 clinical results on QIV seasonal VLPs in healthy adults and elderly

·         Comparison of humoral and cell-mediated immune responses induced by VLPs

Andrew Catchpole
Influenza & Respiratory
3:10

Utilizing human challenge studies to accelerate the development of respiratory vaccines

Session title TBC

Influenza & Respiratory
3:55

Results of a PhIa study of a universal influenza vaccine in healthy adults

  • The promise of prevention: A novel universal vaccine virus Protection from drifted or mismatched flu strains
  • Breadth of protection in multiple age groups
4:10

Networking coffee break

Dr Cheryl Keech
Influenza & Respiratory
4:40

Operational considerations for global respiratory studies – Using seasonality to guide study execution

Dr Giuseppe Ciaramella
Influenza & Respiratory
5:10

Clinical data from our pandemic influenza mRNA vaccines (H7N9 and H10N8)

Nigel Silman
Influenza & Respiratory
5:40

Rapid protection & immunization against the next airborne pandemic

  • Infectious diseases emerge and mutate with high frequency
  • Conventional vaccination strategies take too long to positively affect the outcome of pandemics
  • We present an innovative technology to address the required rapidity and avoid selection of protective antigens
  • The device has been tested with both bacterial and viral pathogens and data from a study with influenza will be presented
Nigel Silman, Senior Business Development Manager, Public Health England
Dr Thomas Muster
Influenza & Respiratory
5:55

Phase 2 influenza vaccine shows broad cross-protection and superiority in nonclinical heterologous challenge

6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 20/Feb/18 09:36

Influenza & Respiratory, Thursday 5 April 2018

The Rise of AMR: Vaccine Development Against Bacterial Infections

Dr Rino Rappuoli
Influenza & Respiratory
09:10

Results on developing a new pertussis vaccine – Opportunities for maternal

·         The need for a new pertussis vaccine with longer lasting immunity

·         Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers

Dr Alessandro Sette
Influenza & Respiratory
09:40

Immune profiling techniques to help develop a more effective pertussis vaccine

10:40

Networking coffee break

Dr Ann Ginsberg
Influenza & Respiratory
11:30

Recent progress in clinical TB vaccine development

Dr Simona Rondini
Influenza & Respiratory
12:00

Presenting early stage development of a vaccine to prevent the bacterial infections that exacerbate Chronic Obstructive Pulmonary Disease (COPD)

·         COPD is a very common, chronic, progressive, respiratory illness of adults, which can be triggered by bacterial infections

·         A vaccine to prevent these respiratory infections could modify the clinical progression of COPD, and improve quality of life

12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

Dr Angela Shen
1:40

Report on U.S. vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development

  • A combined effort from HHS, NIH, CDC, FDA, BARDA to promote innovation in the development of vaccines that minimize the burden of infectious disease
  • What is the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders
  • Identifying whether obstacles exist that inhibit the development of beneficial vaccines
  • Recommendations on how best to promote and incentivize vaccine innovation and development
Dr Jeffrey Stoddard
2:10

Zoster vaccine recombinant, adjuvanted: A journey from research to approval

  • Non-live, recombinant vaccine to help prevent herpes zoster (shingles), combining glycoprotein E with an adjuvant system, AS01
  • Sharing positive results from Phase III revaccination study 
Dr Walter A Orenstein
2:40

With polio eradication succeeding, should measles eradication come next?

  • Changing the perception from polio: Focusing on measles elimination to build our overall immunization program
  • Using a “diagonal” approach when dealing with highly contagious preventable diseases like measles
  • Surveillance -  a weakness in our system?
  • Cost of controlling outbreaks and the consequences
Dr Paul Offit
3:10

Vaccine hesitancy: How to respond to the media to advance better health

  • Challenges to communicating science through the opaque prism of the media
  • How certain cultural biases can influence the perception of science 
3:40

3:40 Chair closing remarks and end of congress

last published: 20/Feb/18 09:36

 

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071